Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
23 11 2021
23 11 2021
Historique:
received:
28
04
2021
accepted:
13
08
2021
pubmed:
2
10
2021
medline:
30
11
2021
entrez:
1
10
2021
Statut:
ppublish
Résumé
Extracellular vesicles (EV) have been implicated in diverse biological processes, including intracellular communication, transport of nucleic acids, and regulation of vascular function. Levels of EVs are elevated in cancer, and studies suggest that EV may stimulate thrombosis in patients with cancer through expression of tissue factor. However, limited data also implicate EV in the activation of the contact pathway of coagulation through activation of factor XII (FXII) to FXIIa. To better define the ability of EV to initiate contact activation, we compared the ability of EV derived from different cancer cell lines to activate FXII. EV from all cell lines activated FXII, with those derived from pancreatic and lung cancer cell lines demonstrating the most potent activity. Concordant with the activation of FXII, EV induced the cleavage of high molecular weight kininogen (HK) to cleaved kininogen. We also observed that EVs from patients with cancer stimulated FXII activation and HK cleavage. To define the mechanisms of FXII activation by EV, EV were treated with calf intestinal alkaline phosphatase or Escherichia coli exopolyphosphatase to degrade polyphosphate; this treatment blocked binding of FXII to EVs and the ability of EV to mediate FXII activation. In vivo, EV induced pulmonary thrombosis in wild-type mice, with protection conferred by a deficiency in FXII, HK, or prekallikrein. Moreover, pretreatment of EVs with calf intestinal alkaline phosphatase inhibited their prothrombotic effect. These results indicate that polyphosphate mediates the binding of contact factors to EV and that EV-associated polyphosphate may contribute to the prothrombotic effects of EV in cancer.
Identifiants
pubmed: 34597365
pii: 477134
doi: 10.1182/bloodadvances.2021005116
pmc: PMC8759128
doi:
Substances chimiques
Polyphosphates
0
Factor XII
9001-30-3
Prekallikrein
9055-02-1
Factor XIIa
EC 3.4.21.38
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4741-4751Subventions
Organisme : NHLBI NIH HHS
ID : U01 HL143402
Pays : United States
Informations de copyright
© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1748-1760
pubmed: 30354195
Blood. 2013 Sep 12;122(11):1873-80
pubmed: 23798713
Cells. 2019 Jul 13;8(7):
pubmed: 31337034
Thromb Res. 2018 Jun;166:54-59
pubmed: 29656167
Biochim Biophys Acta. 2001 Jun 11;1547(2):254-61
pubmed: 11410281
Cell Commun Signal. 2019 Jul 10;17(1):73
pubmed: 31291956
J Biol Chem. 1979 Dec 10;254(23):12020-7
pubmed: 500690
Thromb Res. 2010 Apr;125 Suppl 2:S89-91
pubmed: 20434015
J Thromb Haemost. 2012 Jul;10(7):1363-70
pubmed: 22520016
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):772-786
pubmed: 29419408
Blood. 2015 Sep 10;126(11):1379-89
pubmed: 26153520
Nat Commun. 2016 Sep 06;7:12616
pubmed: 27596064
Blood. 2012 Dec 20;120(26):5103-10
pubmed: 22968458
J Thromb Haemost. 2016 Jan;14(1):28-39
pubmed: 26565070
J Thromb Haemost. 2007 Mar;5(3):632-4
pubmed: 17319909
Best Pract Res Clin Haematol. 2009 Mar;22(1):35-47
pubmed: 19285271
PLoS One. 2009;4(4):e5219
pubmed: 19381331
J Clin Oncol. 2009 Oct 10;27(29):4839-47
pubmed: 19720906
Int J Biol Sci. 2019 Jan 6;15(1):1-11
pubmed: 30662342
J Thromb Haemost. 2007 Mar;5(3):520-7
pubmed: 17166244
J Biol Chem. 2009 Nov 6;284(45):31291-302
pubmed: 19758999
Thromb Res. 2014 May;133 Suppl 2:S35-8
pubmed: 24862143
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Front Med (Lausanne). 2019 Apr 12;6:76
pubmed: 31106204
Science. 1983 Dec 9;222(4628):1129-32
pubmed: 6648524
Curr Opin Hematol. 2019 Sep;26(5):349-356
pubmed: 31261175
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Neoplasia. 1999 Apr;1(1):50-62
pubmed: 10935470
J Thromb Haemost. 2019 Aug;17(8):1261-1264
pubmed: 31231949
Science. 1981 May 22;212(4497):923-4
pubmed: 7195067
J Clin Invest. 2016 Apr 1;126(4):1208-15
pubmed: 27035812
Thromb J. 2015 May 06;13:17
pubmed: 25949215
Blood. 2012 Jun 21;119(25):5972-9
pubmed: 22517894
Clin Cancer Res. 2019 Jan 1;25(1):266-276
pubmed: 30287549
Thromb Res. 2013 Aug;132(2):180-4
pubmed: 23856554
Blood. 2013 Aug 22;122(8):1478-86
pubmed: 23782934
Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):903-8
pubmed: 16410357
J Cell Sci. 2010 May 15;123(Pt 10):1603-11
pubmed: 20445011
Gynecol Oncol. 2017 Jul;146(1):146-152
pubmed: 28501328
PLoS One. 2018 Nov 9;13(11):e0207387
pubmed: 30412630
J Extracell Vesicles. 2015 May 14;4:27066
pubmed: 25979354
Transl Res. 2020 Nov;225:33-53
pubmed: 32645431
Biochem J. 2016 Oct 1;473(19):3031-47
pubmed: 27474409
Int J Mol Sci. 2019 Jun 11;20(11):
pubmed: 31212641
Cancers (Basel). 2018 Oct 11;10(10):
pubmed: 30314362
Front Pharmacol. 2013 Mar 06;4:21
pubmed: 23508692
J Fluoresc. 2008 Sep;18(5):859-66
pubmed: 18210191
J Thromb Haemost. 2013 Jul;11(7):1341-52
pubmed: 23659638
Semin Thromb Hemost. 2017 Nov;43(8):814-826
pubmed: 28346966
J Allergy Clin Immunol. 2017 Dec;140(6):1700-1703.e8
pubmed: 28782632
Nat Rev Clin Oncol. 2020 Dec;17(12):719-720
pubmed: 32943766
Thromb Res. 2016 May;141 Suppl 2:S4-7
pubmed: 27207422
Blood. 2011 Dec 22;118(26):6963-70
pubmed: 21976677
Blood. 1986 Aug;68(2):455-62
pubmed: 3730610